Kymab Limited, a pioneering biopharmaceutical company headquartered in Great Britain, focuses on the development of innovative therapies for autoimmune diseases and cancer. Founded in 2010, Kymab has made significant strides in the biotechnology sector, particularly with its proprietary antibody platform, which enables the creation of unique monoclonal antibodies. The company’s flagship product, KY1005, is designed to modulate immune responses, showcasing Kymab's commitment to addressing unmet medical needs. With a strong presence in both the UK and the US, Kymab has established itself as a key player in the biopharmaceutical industry, recognised for its cutting-edge research and development capabilities. Notable achievements include successful clinical trials and strategic partnerships that enhance its market position and drive future growth.
How does Kymab Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Kymab Limited's score of 23 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Kymab Limited, headquartered in Great Britain, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or climate commitments. However, the absence of data may indicate that the company is in the early stages of developing its sustainability strategy or reporting framework. As the industry increasingly prioritises climate action, Kymab may be expected to establish clear targets and initiatives in the future to align with global climate goals.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Kymab Limited is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.